{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immediate+Release+%28IR%29+Formulation",
    "query": {
      "intervention": "Immediate Release (IR) Formulation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 59,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immediate+Release+%28IR%29+Formulation&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T19:08:36.418Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06477926",
      "title": "A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-668 IR",
          "type": "DRUG"
        },
        {
          "name": "ABBV-668 ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 25,
      "start_date": "2024-07-09",
      "completion_date": "2024-09-20",
      "has_results": false,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06477926"
    },
    {
      "nct_id": "NCT01686217",
      "title": "A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics of ASP015K",
        "Food Effect",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ASP015K ER",
          "type": "DRUG"
        },
        {
          "name": "ASP015K IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-06",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2015-09-01",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01686217"
    },
    {
      "nct_id": "NCT02939183",
      "title": "Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Immediate Release (IR) Formulation",
          "type": "DRUG"
        },
        {
          "name": "Gastro-Retentive (GR) Formulation",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 61,
      "start_date": "2017-01-17",
      "completion_date": "2022-10-06",
      "has_results": true,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 13,
      "location_summary": "West Hollywood, California • Tampa, Florida • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02939183"
    },
    {
      "nct_id": "NCT00782600",
      "title": "Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "suspension IR",
          "type": "DRUG"
        },
        {
          "name": "CR 1",
          "type": "DRUG"
        },
        {
          "name": "CR 2",
          "type": "DRUG"
        },
        {
          "name": "CR 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-07",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2009-06-09",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782600"
    },
    {
      "nct_id": "NCT04881747",
      "title": "A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lasmiditan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2021-05-14",
      "completion_date": "2021-07-24",
      "has_results": true,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04881747"
    },
    {
      "nct_id": "NCT05106309",
      "title": "Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "10 mg CVL-231 as IR formulation",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 as slow-release MR formulation",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 as medium release MR formulation",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 as fast release MR formulation",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 Target Release, Fasted",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 Target Release, Fed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerevel Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-12-29",
      "completion_date": "2022-02-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05106309"
    },
    {
      "nct_id": "NCT02357459",
      "title": "Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "FX006",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TCA IR 40",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 486,
      "start_date": "2015-01",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357459"
    },
    {
      "nct_id": "NCT02468583",
      "title": "Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-traumatic Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "FX006 32 mg",
          "type": "DRUG"
        },
        {
          "name": "TCA IR 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "20 Years to 50 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-02",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02468583"
    },
    {
      "nct_id": "NCT05081245",
      "title": "ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "ML-004 (IR)/(ER) tablet",
          "type": "DRUG"
        },
        {
          "name": "ML-004 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MapLight Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 168,
      "start_date": "2022-09-13",
      "completion_date": "2026-04-17",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 24,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Glendale, California + 21 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Rafael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05081245"
    },
    {
      "nct_id": "NCT04018001",
      "title": "Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1057,
      "start_date": "2019-04-12",
      "completion_date": "2019-04-25",
      "has_results": true,
      "last_update_posted_date": "2024-04-03",
      "last_synced_at": "2026-09-29T19:08:36.418Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04018001"
    }
  ]
}